Revolution Medicines' Rasonque shows 42% response and 16-month survival in NSCLC subgroup

Data from a subgroup of an earlier trial, described by Truist Securities as the most relevant to Revolution Medicines' ongoing Phase 3 study, reported a 42% overall response rate and a median overall survival of 16 months in patients with RAS‑mutant non‑small cell lung cancer (NSCLC).

The results come from a Phase 1/2 trial of Rasonque (daraxonrasib) in previously treated advanced RAS‑mutant NSCLC and were published in The New England Journal of Medicine, providing incremental but constructive support for the company's NSCLC strategy.

In the dose cohort receiving 160‑220 mg, 38 docetaxel‑naive patients who had prior platinum‑based chemotherapy and anti‑PD-(L)1 therapy achieved a 42% overall response rate, median progression‑free survival of 8.3 months, and median overall survival of 16 months, with no Grade 4 or 5 safety events reported.